NCT01047566 - Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE) | Biotech Hunter

Enrollment

183

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Atrial Fibrillation

Interventions

DRUG

Dronedarone

Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)

DRUG

Beta blocker or calcium antagonist or digoxin

Dose increase of beta blocker or calcium antagonist or digoxin

Trial Locations (1)

Sanofi-Aventis Administrative Office, PE Gouda